Propyl gallate-induced platelet aggregation in patients with end-stage renal disease: The influence of the haemodialysis procedure

Nephrology

Volumn 11, Issue 1, 2006, Pages 3-8

  Eleftheriadis, Theodoros ^a,c   Antoniadi, Georgia ^a   Liakopoulos, Vassilios ^b   Tsiandoulas, Apostolos ^a   Barboutis, Konstantinos ^a   Stefanidis, Ioannis ^b  

^a General District Hospital of Serres   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c NONE   (Greece)

Author keywords

Erythropoietin; Haemodialysis; Low molecular weight heparin; Platelet aggregation; Propyl gallate

Indexed keywords

ACETIC ACID DERIVATIVE; CELLULOSE DIACETATE; GALLIC ACID PROPYL ESTER; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; POLYSULFONE; RECOMBINANT ERYTHROPOIETIN; TINZAPARIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTERIOVENOUS FISTULA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIALYSIS MEMBRANE; DRUG MEGADOSE; EVALUATION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INTRAVENOUS CATHETER; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE DYSFUNCTION; VASCULAR ACCESS;

FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PLATELET AGGREGATION; PROPYL GALLATE; RENAL DIALYSIS;

EID: 33645354046     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00526.x     Document Type: Article

References (41)

1. Weigert AL Schafer AI. Uremic bleeding: Pathogenesis and therapy. Am. J. Med. Sci. 1998 316 94 104.
2. Malyszko J Malyszko JS Mysliwiec M. Comparison of hemostatic disturbances between patients on CAPD and patients on hemodialysis. Perit. Dial. Int. 2001 21 158 65.
3. Gawaz MP Dobos G Spath M Schollmeyer P Gurland HJ Mujais SK. Impaired function of platelet membrane glycoprotein IIb-IIIa in end-stage renal disease. J. Am. Soc. Nephrol. 1994 5 36 46.
4. Moal V Brunet P Dou L Morange S Sampol J Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol. Dial. Transplant. 2003 18 1834 41.
5. Eknoyan G Brown CH. Biochemical abnormalities of platelets in renal failure. Evidence for decreased platelet serotonin, adenosine diphosphate and Mg-dependent adenosine triphosphatase. Am. J. Nephrol. 1981 1 17 23.
6. Pietrzak I Komarnicki M Zaremba-Drobnik D. Platelet aggregation and prostaglandin metabolism in uremic patients. Am. J. Kidney Dis. 2001 38 S111 14.
7. Noris M Remuzzi G. Uremic bleeding: Closing the circle after 30 years of controversies? Blood 1999 94 2569 74.
8. Maurin N Fitzner S Fritz H Gladziwa U Hägel J Stefanidis I. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis. Clin. Nephrol. 1995 43 196 200.
9. Gordge MP Leaker B Patel A Oviasu E Cameron JS Neild GH. Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation. Thromb. Res. 1990 57 171 82.
10. Van Geet C Hauglustaine D Verresen L Vanrusselt M Vermylen J. Haemostatic effects of recombinant human erythropoietin in chronic haemodialysis patients. Thromb. Haemost. 1989 61 117 21.
11. Huraib S al-Momen AK Gader AM Mitwalli A Sulimani F Abu-Aisha H. Effect of recombinant human erythropoietin (rHuEPO) on the hemostatic system inchronic hemodialysis patients. Clin. Nephrol. 1991 36 252 7.
12. Zwaginga JJ Ijsseldijk MJ de Groot PG et al. Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb. Haemost. 1991 66 638 47.
13. Cases A Escolar G Reverter JC et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int. 1992 42 668 72.
14. El-Shahawy MA Francis R Akmal M Massry SG. Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in hemodialysis patients. Clin. Nephrol. 1994 41 308 13.
15. Akizawa T Kinugasa E Kitaoka T Koshikawa S. Effects of recombinant human erythropoietin and correction of anemia on platelet function in hemodialysis patients. Nephron 1991 58 400 406.
16. Zirkman DM Zeigler ZR Fraley DS Bruns FJ Adler S. Evaluation of platelet hyperfunction in hemodialysis patients receivingrecombinant human erythropoietin. Am. J. Kidney Dis. 1993 21 31 7.
17. Matsuo T Matsuo M Kario K Suzuki S. Characteristics of heparin-induced platelet aggregates in chronic hemodialysis with long-term heparin use. Haemostasis 2000 30 249 57.
18. Charvat J Konig J Blaha J. Is heparin responsible for enhanced platelet aggregation after haemodialysis? Nephron 1986 44 89 91.
19. Suzuki T Ota K Naganuma S et al. Clinical application of Fragmin (FR-860) in hemodialysis: Multicenter cooperative study in Japan. Semin. Thromb. Hemost. 1990 16 S1 46 54.
20. Borm JJ Krediet R Sturk A ten Cate JW. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: A randomized cross-over study. Haemostasis 1986 16 S2 59 68.
21. Ljungberg B Beving H Egberg N Johnsson H Vesterqvist O. Immediate effects of heparin and LMW heparin on some platelet and endothelial derived factors. Thromb. Res. 1988 51 209 17.
22. Sakuragawa N Takahashi K. Comparative studies on properties of unfractionated and low molecular weight heparin. Semin. Thromb. Hemost. 1990 16 Suppl 5 11.
23. Kawano K Ikeda Y Handa M et al. Enhancing effect by heparin on shear-induced platelet aggregation. Semin. Thromb. Hemost. 1990 16 Suppl 60 65.
24. Burgess JK Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur. J. Haematol. 1997 58 279 85.
25. Winter M Frampton G Bennett A Machin SJ Cameron JS. Synthesis of thromboxane B2 in uraemia and the effects of dialysis. Thromb. Res. 1983 30 265 72.
26. Sreedhara R Itagaki I Lynn B Hakim RM. Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am. J. Kidney Dis. 1995 25 555 63.
27. Sloand JA Sloand EM. Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J. Am. Soc. Nephrol. 1997 8 799 803.
28. Kuragano T Kuno T Takahashi Y et al. Comparison of the effects of cellulose triacetate and polysulfone membrane onGPIIb/IIIa and platelet activation. Blood Purif. 2003 21 176 82.
29. Kawabata K Nakai S Miwa M et al. Platelet GPIIb/IIIa is activated and platelet-leukocyte coaggregates formed in vivo during hemodialysis. Nephron 2002 90 391 400.
30. Gawaz MP Mujais SK Schmidt B Blumenstein M Gurland HJ. Platelet-leukocyte aggregates during hemodialysis: Effect of membrane type. Artif. Organs 1999 23 29 36.
31. Speck RE. Comparison of slide platelet aggregation reagents. Am. Clin. Lab. 1994 13 22 3.
32. Speck RE Melvin JR. A Comparison of the slide platelet aggregation procedure with the bleeding time test. Am. Clin. Lab. 1994 13 12 13.
33. Xiao H Kovics R Jackson V Remick DG. Effects of platelet inhibitors on propyl gallate-induced platelet aggregation, protein tyrosine phosphorylation, and platelet factor 3 activation. Blood Coagul. Fibrinolysis 2004 15 199 206.
34. Van Cott EM Laposata M. 'Coagulation.' In Jacobs DS De Mott WR Oxlay DK eds. The Laboratory Test Handbook 5th edn. Cleveland Lexi-Comp 2001 327 58.
35. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: An analysis of error. J. Am. Soc. Nephrol. 1993 4 1205 13.
36. Stejskal D Proskova J Petrzelova A et al. Application of cationic propyl gallate as inducer of thrombocyte aggregation for evaluation of effectiveness of antiaggregation therapy. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech Repub. 2001 145 69 74.
37. Schwartz KA Schwartz DE Pittsley RA et al. A new method for measuring inhibition of platelet function by nonsteroidal antiinflammatory drugs. J. Lab. Clin. Med. 2002 139 227 33.
38. Stenver D Jeppesen L Nielsen B et al. The effect of erythropoietin on platelet function and fibrinolysis in chronic renal failure. Int. J. Artif. Organs 1994 17 141 5.
39. Fuste B Escolar G Cases A Lopez-Pedret J Ordinas A Diaz-Ricart M. Novel erythropoiesis stimulating protein exerts an effect on platelet function in uremia equivalent to that exerted by recombinant human erythropoietin. Haematologica 2002 87 551 3.
40. Sreedhara R Itagaki I Hakim RM. Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am. J. Kidney Dis. 1996 27 355 64.
41. Sobel M Fish WR Toma N et al. Heparin modulates integrin function in human platelets. J. Vasc. Surg. 2001 33 587 94.